にきび治療薬の市場規模、シェア、動向、予測：にきびタイプ、薬剤クラス別、薬剤タイプ、投与経路、地域別、2025～2033年

世界のにきび治療薬市場規模は2024年に72億米ドルに達しました。今後、IMARC Groupは、市場は2033年までに112億米ドルに達し、2025～2033年にかけて4.9%の成長率（CAGR）を示すと予測しています。市場は主に、成人と青少年におけるにきびの有病率の上昇、スキンケアに対する意識の高まりと重視、革新的な治療のための医薬品の研究開発における継続的な進歩、ソーシャルメディアの影響力の台頭によって牽引されています。

世界のにきび治療薬市場動向

にきびの有病率の増加

世界中の成人と青少年におけるにきびの有病率の増加が、主ににきび治療薬市場の統計を牽引しています。さらに、思春期におけるホルモンの変化の増加、個人の高いストレスレベル、食生活の乱れや不十分なスキンケア習慣を含むいくつかのライフスタイル要因が、市場の成長を促進すると予測されています。これに加えて、革新的で利用しやすく信頼性の高いにきび治療薬を創造するための大手製薬企業による広範な研究開発努力も、市場拡大にプラスの影響を与えています。例えば、ClickPharmacyが発表したデータでは、英国の成人の34％が、人生のある時点でにきびに悩まされた経験があると報告されています。また、女性の2.5％に対し、男性の6.1％がにきびに悩まされているといいます。また、Sahel Medical Journal誌が発表した紙製によると、南ナイジェリアにおける尋常性ざ瘡の有病率は37.3％で、男性（36.7％）よりも女性（37.6％）の方が高いです。このため、多くの主要企業が、にきびに悩む多くの患者層にアプローチするため、適切なにきび治療薬ソリューションの導入に注力しています。例えば、サン・ファーマシューティカルインダストリーズ社は2023年6月、にきびやにきび跡の治療に使用されるWINLEVIクリームについて、同国の保健規制当局であるカナダ保健省から承認を取得しました。

スキンケアに対する意識の高まりと重視

スキンケアや身だしなみに関する意識の高まりが、にきび治療薬市場の成長を後押ししています。さらに、特に新興経済諸国では、透明でシミのない肌の実現を支援するスキンケア製品や治療に対する個人の支出が膨らんでいることも、世界市場を活性化しています。これに加えて、ソーシャルメディアや有名人の推薦の影響力の増大や、皮膚の外観を向上させる治療に対する需要の高まりも、市場成長にプラスの影響を与えています。例えば、ガルデルマは新しいデジタルキャンペーンを開始しました。アクリーフ（トリファロテン）クリームによる局所にきび治療薬の「Me Being Me」です。同社は、20年以上ぶりに尋常性ざ瘡の承認を得た新規レチノイド分子であるアクリーフについて患者を啓発しました。これに加えて、ストライククラブは、にきび、黒ずみ、白斑、毛穴の詰まりを防ぐノックアウト・アダパレン・ジェルでレチノイドによるにきび治療薬を発表しました。さらに、2023年9月、マークサンズ・ファーマはインドのテバ・ファーマシューティカルズの買収を完了し、テバの重要な医薬品を顧客と患者に継続的に供給しています。

医薬品研究開発の進歩

にきび治療薬のための革新的かつ効率的な製剤を開発するための医薬品研究開発の継続的な進歩は、開発にプラスの影響を与えています。これに加えて、最新かつ改良されたにきび治療薬の研究と導入における規制当局による投資の増加も、市場拡大を後押ししています。さらに、改良されたドラッグデリバリーシステムの人気の高まり、新規有効成分の発見、にきびの様々な側面を対象とする併用療法の広範な採用が、にきび薬市場の収益をさらに刺激しています。例えば、ガルデルマ社は、マサチューセッツ州ボストンで開催された米国皮膚科学会（AAD）年次総会において、「ツイネオ」クリーム0.1%/3%の米国での発売を発表しました。トワイネオクリームは、トレチノイン0.1％と過酸化ベンゾイル（BPO）3％の2-in-1配合剤で、中等度から重度の顔面にきびを迅速に治療することが証明された最初で唯一の製品です。さらに2023年5月、ボシュヘルスカンパニーズ社は、米国食品医薬品局（FDA）が処方薬ユーザーフィー法（PDUFA）により、治験薬IDP-126（クリンダマイシン1.2％/アダパレン0.15％/過酸化ベンゾイル3.1％）ゲルの新薬承認申請（NDA）を受理したと発表しました。

にきび治療薬の世界市場セグメンテーション

尋常性ざ瘡のセグメントでは、非炎症性ざ瘡の有病率の高さ、市販薬へのアクセスの増加、シミのない透明な肌への願望が主に市場の成長を牽引しています。このほか、強力な抗炎症剤に対する需要の高まりや、効果的なにきび治療薬ソリューションの開発のための研究活動の活発化が、炎症性セグメントの市場を活性化しています。さらに、処方箋ベース医薬品に対するニーズの高まり、先進的な治療法の人気の高まり、手術後のスキンケアに対する要求の高まり、美容手術の新たな動向が、嚢胞性セグメントと手術後/創傷セグメントにおけるにきび治療薬市場の拡大を促進しています。

市場を独占するレチノイド

にきび治療薬におけるレチノイドの利用に対する意識の高まりが、このセグメントの市場成長を大きく後押ししています。これに加えて、皮膚細胞のターンオーバーを調整し、面皰（黒ずみや白斑）の形成を予防し、炎症を抑えるレチノイドの能力により、効果的なにきび治療薬に対する医療従事者や個人の幅広い製品ニーズが、市場の成長をさらに促進しています。

市販薬（OTC）の入手のしやすさとセルフケアに対する個人の関心の高まりが、このセグメントにおけるにきび薬市場の成長を後押ししています。これに加えて、一般的な肌の悩みに対する消費者の間で、スーパーマーケットや薬局、オンラインストアで簡単に入手できる即効性のある治療へのニーズが高まっていることも、にきび治療薬の世界の需要にプラスの影響を与えています。例えば、サンファーマはTLCネットワークの皮膚科医サンドラ・リー博士と提携し、「AH-ha！It's Acne Hormones』というキャンペーンを行りました。このキャンペーンでは、年齢、性別、民族など多様な人々が登場し、米国の人々にOTC製品を含む効果的なスキンケア方法を指導しました。

外用剤が市場で最大のシェアを占める

局所治療の利便性は、にきび治療薬市場展望において重要な役割を果たしています。これに加えて、副作用が少なく、より良い結果をもたらす革新的な製剤の導入に向けた製薬セクタにおける研究開発の継続的な取り組みも、このセグメントの市場成長の触媒となっています。例えば、米国FDAは、他の治療法が使用できない、あるいは他の治療法では十分な症状緩和が得られない12歳以上の軽度から中等度のアトピー性皮膚炎患者を対象としたクリーム剤Opzelura（ルキソリチニブ）を承認しました。

北米が明確な優位性を示し、最大のにきび治療薬市場シェアを占める

本レポートでは、北米の（米国、カナダ）、アジア太平洋の（中国、日本、インド、韓国、オーストラリア、インドネシア、その他）、欧州の（ドイツ、フランス、英国、イタリア、スペイン、ロシア、その他）、ラテンアメリカ（ブラジル、メキシコ、その他）、中東・アフリカのを含む主要地域市場についても包括的に分析しています。報告書によると、北米が最大の市場シェアを占めています。

北米がにきび治療薬市場の最大セグメントを占めたのは、その先進的ヘルスケアインフラと個人の支出能力の膨張によるものです。これに加えて、青少年や成人のにきび有病率の高さ、最先端の医療技術の開発、医療専門家や皮膚科医へのアクセスのしやすさなども、この地域の市場成長を後押ししています。これに加えて、外見や美しさを維持しようという個人の志向の高まりも、市場成長にプラスの影響を与えています。例えばカナダでは、ボシュヘルスの子会社であるオルソ・デルマトロジクス社が、193人の尋常性ざ瘡患者を対象に検査した3化合物配合ゲル、IDP-126の2回目の第III相臨床検査から良好なトップラインデータを発表しました。この臨床検査では、12週目に炎症性病変と非炎症性病変の両方の問題で減少がみられました。IDP-126はアダパレン、レチノール、抗菌性過酸化ベンゾイルを配合しています。

競合情勢

世界の競合情勢は、にきび治療薬のための革新的で効果的なソリューションを提供しようとする多様な製薬企業やヘルスケア企業によって特徴づけられています。ユーザーの要望により具体的な参入企業についてはここでは言及しないが、市場が研究開発、戦略的提携、製品の多様化を通じて競争を促進していることは重要です。このセグメントの企業は、軽度のものから重度のものまで、様々なタイプのにきびを対象とした新薬や治療法を配合するため、継続的に研究開発に投資しています。皮膚科医やスキンケアの専門家とのパートナーシップは、自社製品を推奨する上で役立ち、信頼性と市場リーチを拡大します。さらに、デジタルマーケティングやソーシャルメディアを含むマーケティング戦略は、製品の販売促進や効果的なにきび管理について消費者を教育する上で極めて重要な役割を果たしています。競合情勢は、にきび治療薬を求める個人の多様なニーズに対応する上で、品質、安全性、革新性の重要性を強調しており、最終的には幅広い選択肢と改善されたソリューションによって消費者に利益をもたらしています。

この市場調査レポートは、市場の競合情勢についても包括的な分析を行っています。市場構造、主要企業のポジショニング、主要成功戦略、競合ダッシュボード、企業評価象限などの競合分析が本レポートで取り上げられています。また、すべての主要企業の詳細なプロファイルが提供されています。にきび治療薬産業の主要市場参入企業には以下の企業が含まれます。

本レポートでお答えする主要質問

• にきび治療薬の世界市場規模は？
• 2025～2033年におけるにきび治療薬世界市場の予想成長率は？
• にきび治療薬の世界市場を牽引する主要因は何か
• にきび治療薬の世界市場におけるCOVID-19の影響は？
• にきび治療薬の世界市場における薬剤クラス別内訳は？
• にきび治療薬の世界市場における投与経路による区分は？
• にきび治療薬の世界市場における主要地域は？
• にきび治療薬の世界市場における主要参入企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査の目的
• ステークホルダー
• データソース
  • 一次情報
  • 二次情報
• 市場推定
  • ボトムアップアプローチ
  • トップダウンアプローチ
• 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界のにきび治療薬市場

• 市場概要
• 市場実績
• COVID-19の影響
• 市場予測

第6章 市場内訳：にきびタイプ別

• コメドナル
• 炎症性
• 嚢胞性
• 術後/創傷

第7章 市場内訳：薬剤クラス別

• レチノイド
• 抗生物質
• ホルモン剤
• 併用薬
• その他

第8章 市場内訳：薬剤タイプ別

• 市販薬
• 処方薬

第9章 市場内訳：投与経路別

• 局所
• 経口
• 注射

第10章 市場内訳：地域別

• 北米
  • 米国
  • カナダ
• アジア太平洋
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア
  • インドネシア
  • その他
• 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • ロシア
  • その他
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • その他
• 中東・アフリカ

第11章 SWOT分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 価格分析

第15章 競合情勢

• 市場構造
• 主要企業
• 主要企業のプロファイル
  • Allergan Plc
  • Bausch Health Companies Inc.
  • Bayer Aktiengesellschaft
  • Cipher Pharmaceuticals Inc.
  • Galderma Holding SA
  • Johnson & Johnson
  • Pfizer Inc.
  • Reckitt Benckiser Group Plc
  • Skinvisible Pharmaceuticals Inc.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.

List of Figures

• Figure 1: Global: Acne Drugs Market: Major Drivers and Challenges
• Figure 2: Global: Acne Drugs Market: Sales Value (in Billion USD), 2019-2024
• Figure 3: Global: Acne Drugs Market: Breakup by Acne Type (in %), 2024
• Figure 4: Global: Acne Drugs Market: Breakup by Drug Class (in %), 2024
• Figure 5: Global: Acne Drugs Market: Breakup by Drug Type (in %), 2024
• Figure 6: Global: Acne Drugs Market: Breakup by Route of Administration (in %), 2024
• Figure 7: Global: Acne Drugs Market: Breakup by Region (in %), 2024
• Figure 8: Global: Acne Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
• Figure 9: Global: Acne Drugs (Comedonal) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 10: Global: Acne Drugs (Comedonal) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 11: Global: Acne Drugs (Inflammatory) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 12: Global: Acne Drugs (Inflammatory) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 13: Global: Acne Drugs (Cystic) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 14: Global: Acne Drugs (Cystic) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 15: Global: Acne Drugs (Postsurgical/Wound) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 16: Global: Acne Drugs (Postsurgical/Wound) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 17: Global: Acne Drugs (Retinoids) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 18: Global: Acne Drugs (Retinoids) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 19: Global: Acne Drugs (Antibiotics) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 20: Global: Acne Drugs (Antibiotics) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 21: Global: Acne Drugs (Hormonal Agents) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 22: Global: Acne Drugs (Hormonal Agents) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 23: Global: Acne Drugs (Combination Drugs) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 24: Global: Acne Drugs (Combination Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 25: Global: Acne Drugs (Other Drug Classes) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 26: Global: Acne Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 27: Global: Acne Drugs (OTC Drugs) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 28: Global: Acne Drugs (OTC Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 29: Global: Acne Drugs (Prescription Drugs) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 30: Global: Acne Drugs (Prescription Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 31: Global: Acne Drugs (Topical) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 32: Global: Acne Drugs (Topical) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 33: Global: Acne Drugs (Oral) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 34: Global: Acne Drugs (Oral) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 35: Global: Acne Drugs (Injectable) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 36: Global: Acne Drugs (Injectable) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 37: North America: Acne Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 38: North America: Acne Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 39: United States: Acne Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 40: United States: Acne Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 41: Canada: Acne Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 42: Canada: Acne Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 43: Asia Pacific: Acne Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 44: Asia Pacific: Acne Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 45: China: Acne Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 46: China: Acne Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 47: Japan: Acne Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 48: Japan: Acne Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 49: India: Acne Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 50: India: Acne Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 51: South Korea: Acne Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 52: South Korea: Acne Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 53: Australia: Acne Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 54: Australia: Acne Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 55: Indonesia: Acne Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 56: Indonesia: Acne Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 57: Others: Acne Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 58: Others: Acne Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 59: Europe: Acne Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 60: Europe: Acne Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 61: Germany: Acne Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 62: Germany: Acne Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 63: France: Acne Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 64: France: Acne Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 65: United Kingdom: Acne Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 66: United Kingdom: Acne Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 67: Italy: Acne Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 68: Italy: Acne Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 69: Spain: Acne Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 70: Spain: Acne Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 71: Russia: Acne Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 72: Russia: Acne Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 73: Others: Acne Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 74: Others: Acne Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 75: Latin America: Acne Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 76: Latin America: Acne Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 77: Brazil: Acne Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 78: Brazil: Acne Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 79: Mexico: Acne Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 80: Mexico: Acne Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 81: Others: Acne Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 82: Others: Acne Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 83: Middle East and Africa: Acne Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 84: Middle East and Africa: Acne Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 85: Global: Acne Drugs Industry: SWOT Analysis
• Figure 86: Global: Acne Drugs Industry: Value Chain Analysis
• Figure 87: Global: Acne Drugs Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Global: Acne Drugs Market: Key Industry Highlights, 2024 and 2033
• Table 2: Global: Acne Drugs Market Forecast: Breakup by Acne Type (in Million USD), 2025-2033
• Table 3: Global: Acne Drugs Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
• Table 4: Global: Acne Drugs Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
• Table 5: Global: Acne Drugs Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
• Table 6: Global: Acne Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
• Table 7: Global: Acne Drugs Market Structure
• Table 8: Global: Acne Drugs Market: Key Players

The global acne drugs market size reached USD 7.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 11.2 Billion by 2033, exhibiting a growth rate (CAGR) of 4.9% during 2025-2033. The market is primarily driven by the rising prevalence of acne among adults and adolescents, the increasing awareness and emphasis on skincare, the ongoing advancements in pharmaceutical R&D for innovative treatments, and the emerging social media influence.

Global Acne Drugs Market Trends:

Increasing Prevalence of Acne

The increasing prevalence of acne among adults and adolescents across the globe is primarily driving the acne drug market statistics. Moreover, the rising hormonal changes during puberty, high stress levels of individuals, and several lifestyle factors, including poor diet and inadequate skincare routines are anticipated to propel the market growth forward. Besides this, the extensive research and development efforts by the major pharmaceutical companies for creative innovative, accessible, and reliable acne medications are also positively influencing the market expansion. For instance, the data published by ClickPharmacy reported that 34% of United Kingdom adults have suffered from acne at some point in their lives. The same source mentioned that 6.1% of men are currently suffering from acne when compared to 2.5% of women. Also, the article published by Sahel Medical Journal mentioned that the prevalence of acne vulgaris in South Nigeria was 37.3% with a higher prevalence in females (37.6%) than in males (36.7%). On account of this, numerous key players are focusing on the introduction of adequate acne treatment solutions to reach out to a large patient base suffering from acne. For example, in June 2023, Sun Pharmaceutical Industries Ltd., received approval from Health Canada, the country's health regulator, for its WINLEVI cream, used in treating acne and acne scars.

Growing Awareness and Emphasis on Skincare

The growing emphasis and awareness regarding skincare and personal appearance is augmenting the acne drugs market growth. Moreover, the inflating expenditures by individuals, especially in developing economies, on skincare products and treatments that aid in achieving clear and blemish-free skin are also catalyzing the global market. Besides this, the increasing influence of social media and celebrity endorsements and the escalating demand for therapies that enhance the appearance of the skin are also positively influencing the market growth. For example, Galderma launched a new digital campaign. "Me Being Me" for topical acne treatment with Aklief (trifarotene) Cream. The company educated patients about Aklief, which is the first new retinoid molecule to gain approval for acne vulgaris in more than 20 years. In addition to this, Stryke Club introduced retinoid acne treatment with its Knockout Adapalene Gel that prevents pimples, blackheads, whiteheads, and clogged pores. Moreover, in September 2023, Marksans Pharma completed the acquisition of Teva Pharmaceuticals in India to continue providing an uninterrupted supply of Teva's important medicines to customers and patients.

Advancements in Pharmaceutical Research and Development

The continuous advancements in pharmaceutical research and development for creating innovative and more efficient formulations for acne treatment are positively influencing the market growth. In addition to this, the inflating investments by regulatory authorities in the study and introduction of the latest and improved acne drugs are also propelling the market expansion. Moreover, the growing popularity of improved drug delivery systems, the discovery of novel active ingredients, and the widespread adoption of combination therapies that target various aspects of acne are further catalyzing the acne drug market revenue. For instance, Galderma announced the U.S. launch of its "Twyneo" Cream, 0.1%/3% at the American Academy of Dermatology (AAD) Annual Meeting in Boston, Massachusetts. TWYNEO Cream is the first and only 0.1% tretinoin and 3% benzoyl peroxide (BPO) 2-in-1 combination proven to rapidly treat moderate to severe facial acne. Moreover, in May 2023, Bausch Health Companies Inc. announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for investigational IDP-126 (clindamycin 1.2%/adapalene 0.15%/benzoyl peroxide 3.1%) Gel with a Prescription Drug User Fee Act (PDUFA).

Global Acne Drugs Market Segmentation

Breakup by Acne Type:

• Comedonal
• Inflammatory
• Cystic
• Postsurgical/Wound

In the comedonal segment, the high prevalence of non-inflammatory acne cases, increasing accessibility to over-the-counter remedies, and the desire for clear, blemish-free skin are primarily driving the market growth. Besides this, the escalating demand for potent anti-inflammatory agents and the ongoing research activities for the development of effective acne treatment solutions are catalyzing the market in the inflammatory segment. Moreover, the rising need for prescription-based medications, the growing popularity of advanced therapies, the elevating requirement for post-procedure skincare, and the emerging trend of cosmetic surgeries, are propelling the expansion of the acne drugs market in the cystic and postsurgical/wound segments.

Breakup by Drug Class:

• Retinoids
• Antibiotics
• Hormonal Agents
• Combination Drugs
• Others

Retinoids dominate the market

The rising awareness towards the utilization of retinoids in acne treatment is majorly fueling the market growth in this segment. Besides this, the extensive product need among healthcare professionals and individuals for effective acne treatment, owing to their ability to regulate skin cell turnover, prevent the formation of comedones (blackheads and whiteheads), and reduce inflammation, is augmenting the market growth further.

Breakup by Drug Type:

• OTC Drugs
• Prescription Drugs

The easy accessibility of over-the-counter (OTC) drugs and the increasing individual interest in self-care solutions are bolstering the growth of the acne drug market in this segment. Besides this, the rising need for quick remedies, which are readily available in supermarkets, pharmacies, and online outlets, among consumers for common skin concerns is positively influencing the demand for acne drugs globally. For instance, Sun Pharma teamed up with dermatologist Dr. Sandra Lee on the TLC network to spotlight the role of hormones in the underlying cause of skin acne through a campaign called 'AH-ha! It's Acne Hormones'. The campaign featured a diverse group of people of age, gender, and ethnicity and guided the population of the U.S. to follow an effective skin care regimen that may involve OTC products.

Breakup by Route of Administration:

• Topical
• Oral
• Injectable

Topical holds the largest share in the market

The convenience of topical treatments plays a significant role in the acne drug market outlook, as these products are easy to apply directly to affected areas, making them a preferred choice for several individuals seeking localized acne management. Besides this, the ongoing research and development efforts in the pharmaceutical sector for the introduction of innovative formulations with fewer side effects and better outcomes are also catalyzing the market growth in this segment. For instance, the U.S. FDA approved Opzelura (ruxolitinib), a cream for treating mild to moderate atopic dermatitis in patients aged 12 years and older who are not able to use other treatments or fail to get enough symptom relief from other therapies.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America exhibits a clear dominance, accounting for the largest acne drugs market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America represented the largest segment for the acne drugs market, owing to its advanced healthcare infrastructure and the inflating expenditure capacities of individuals. Besides this, the high prevalence of acne among adolescents and adults, the development of state-of-the-art medical technology, and the easy accessibility to medical professionals and dermatologists are also catalyzing the growth of the market in this region. In addition to this, the rising individual inclination towards maintaining their appearance and beauty is positively influencing the market growth. For instance, in Canada, Bausch Health's subsidiary Ortho Dermatologics announced positive topline data from its second Phase III trial for IDP-126, a three-compound combination gel tested in 193 patients with acne vulgaris. This clinical trial showed reductions in both inflammatory and non-inflammatory lesions at week 12 in both problems. IDP-126 combines adapalene, retinol, and anti-microbial benzoyl peroxide.

Competitive Landscape:

The competitive landscape of the global acne drugs market is characterized by a diverse array of pharmaceutical and healthcare companies striving to offer innovative and effective solutions for acne treatment. While specific players are not mentioned here due to the user's request, it's important to note that the market fosters competition through research and development, strategic collaborations, and product diversification. Companies within this space are continually investing in R&D to formulate new medications and therapies that target various types of acne, ranging from mild to severe cases. Partnerships with dermatologists and skincare experts help in endorsing their products, adding credibility and market reach. Furthermore, marketing strategies, including digital marketing and social media, play a pivotal role in promoting their products and educating consumers about effective acne management. The competitive landscape emphasizes the importance of quality, safety, and innovation in addressing the diverse needs of individuals seeking acne treatments, ultimately benefiting consumers with a wider range of options and improved solutions.

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the major market players in the Acne Drugs industry include:

• Allergan Plc
• Bausch Health Companies Inc.
• Bayer Aktiengesellschaft
• Cipher Pharmaceuticals Inc.
• Galderma Holding SA
• Johnson & Johnson
• Pfizer Inc.
• Reckitt Benckiser Group Plc
• Skinvisible Pharmaceuticals Inc.
• Sun Pharmaceutical Industries Limited
• Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report

• 1.How big is the global acne drugs market?
• 2.What is the expected growth rate of the global acne drugs market during 2025-2033?
• 3.What are the key factors driving the global acne drugs market?
• 4.What has been the impact of COVID-19 on the global acne drugs market?
• 5.What is the breakup of the global acne drugs market based on the drug class?
• 6.What is the breakup of the global acne drugs market based on the route of administration?
• 7.What are the key regions in the global acne drugs market?
• 8.Who are the key players/companies in the global acne drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Acne Drugs Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Acne Type

• 6.1 Comedonal
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Inflammatory
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Cystic
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Postsurgical/Wound
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Drug Class

• 7.1 Retinoids
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Antibiotics
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Hormonal Agents
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Combination Drugs
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Others
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Market Breakup by Drug Type

• 8.1 OTC Drugs
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Prescription Drugs
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast

9 Market Breakup by Route of Administration

• 9.1 Topical
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Oral
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Injectable
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Allergan Plc
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 Bausch Health Companies Inc.
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
  • 15.3.3 Bayer Aktiengesellschaft
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
    • 15.3.3.4 SWOT Analysis
  • 15.3.4 Cipher Pharmaceuticals Inc.
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 Financials
  • 15.3.5 Galderma Holding SA
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
  • 15.3.6 Johnson & Johnson
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
    • 15.3.6.3 Financials
    • 15.3.6.4 SWOT Analysis
  • 15.3.7 Pfizer Inc.
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
    • 15.3.7.3 Financials
    • 15.3.7.4 SWOT Analysis
  • 15.3.8 Reckitt Benckiser Group Plc
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 Skinvisible Pharmaceuticals Inc.
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
  • 15.3.10 Sun Pharmaceutical Industries Limited
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
    • 15.3.10.4 SWOT Analysis
  • 15.3.11 Teva Pharmaceutical Industries Ltd.
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
    • 15.3.11.3 Financials
    • 15.3.11.4 SWOT Analysis